This inventor holds 1 USPTO granted patent. Top assignees: Dcd Inc., Genomine, Inc.. Active years: 2012.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 9 
1 out of 8 
Years Active: 2012
Title: Kyung Mok Park: Innovator in Renal Cell Carcinoma Diagnostics
Introduction
Kyung Mok Park is a notable inventor based in Pohang-si, South Korea. He has made significant contributions to the field of medical diagnostics, particularly in the detection of renal cell carcinoma. His innovative work has the potential to improve early diagnosis and treatment options for patients.
Latest Patents
Kyung Mok Park holds a patent for a diagnostic composition and kit specifically designed for renal cell carcinoma. This patent discloses a composition and kit that utilize several markers, including nicotinamide N-methyltransferase, L-plastin, secretagogin, NM23A, CapG, and C4a anaphylatoxin. These components play a crucial role in identifying renal cell carcinoma, thereby aiding in timely medical intervention.
Career Highlights
Throughout his career, Kyung Mok Park has worked with various companies, including DCD Inc. and Genomine, Inc. His experience in these organizations has allowed him to develop and refine his innovative ideas in the field of diagnostics.
Collaborations
Kyung Mok Park has collaborated with several professionals in his field, including Dong Su Kim and Nam Hoon Cho. These partnerships have contributed to the advancement of his research and the successful development of his patented technologies.
Conclusion
Kyung Mok Park's contributions to renal cell carcinoma diagnostics exemplify the impact of innovation in healthcare. His work not only enhances diagnostic capabilities but also holds promise for improving patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile